A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2013

At a glance

  • Drugs ABT 436 (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 07 Oct 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 04 Jun 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top